1. Home
  2. BLSH vs ERAS Comparison

BLSH vs ERAS Comparison

Compare BLSH & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bullish Ordinary Shares

BLSH

Bullish Ordinary Shares

N/A

Current Price

$19.26

Market Cap

5.8B

Sector

Finance

ML Signal

N/A

Logo Erasca Inc.

ERAS

Erasca Inc.

N/A

Current Price

$13.76

Market Cap

6.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BLSH
ERAS
Founded
2020
2018
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
6.3B
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
BLSH
ERAS
Price
$19.26
$13.76
Analyst Decision
Buy
Buy
Analyst Count
14
10
Target Price
★ $36.15
$25.10
AVG Volume (30 Days)
1.5M
★ 5.1M
Earning Date
11-18-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 36.23
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$49.48
N/A
Revenue Next Year
$12.47
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.80
$2.81
52 Week High
$48.93
$24.28

Technical Indicators

Market Signals
Indicator
BLSH
ERAS
Relative Strength Index (RSI) 31.75 42.80
Support Level N/A $13.18
Resistance Level $25.01 $15.71
Average True Range (ATR) 1.61 1.31
MACD -0.07 -0.13
Stochastic Oscillator 6.34 14.12

Price Performance

Historical Comparison
BLSH
ERAS

About BLSH Bullish Ordinary Shares

Bullish is an institutionally focused global digital asset platform focused on providing market infrastructure and information services. Its objective is to provide mission critical products and services that are designed to help institutions grow their businesses, empower individual investors, and drive the adoption of stablecoins, digital assets, and blockchain technology. It expanded its product offering to provide trusted insights, authoritative news, data, indices and transparent analysis to the digital assets industry while facilitating partnerships, investment opportunities, and community engagement through its flagship Consensus conference.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: